To evaluate the efficacy, safety and tolerability of Hilterapia® (High Intensity Laser Therapy) in the chronic articular inflammatory processes in haemophilic adult patients

ISRCTN ISRCTN02847428
DOI https://doi.org/10.1186/ISRCTN02847428
Secondary identifying numbers HILT-haemophilia-2011
Submission date
27/07/2011
Registration date
13/09/2011
Last edited
14/02/2017
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Haematological Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Haemophilia is an inherited condition that affects the blood's ability to clot, which can lead to bleeding into the joints and inflammation. The aim of this study is to assess the effectiveness, safety and tolerability of high-intensity laser therapy (HILT) for the treatment of joint inflammation in haemophiliac patients.

Who can participate?
Patients aged 18 and over with haemophilia A

What does the study involve?
All participants receive nine applications of HILT (three applications per week over 3 weeks). Pain is assessed before, during and after treatment.

What are the possible benefits and risks of participating?
It is not known for certain whether the participant will benefit, but as HILT is already used successfully in other diseases, it could help. The risks of HILT are the following reactions related to the application area: warm with possibly burning sensation, local sensitivity alteration, tingling, numbness, rush and oedema (build-up of fluid).

Where is the study run from?
IRCCS Ospedale Maggiore di Milano (Italy)

When is the study starting and how long is it expected to run for?
May 2011 to December 2011

Who is funding the study?
Baxter (Italy)

Who is the main contact?
Dr Michele Schino

Contact information

Dr Elena Santagostino
Scientific

Centro Emofilia e Trombosi
Angelo Bianchi Bonomi
Dipartimento di Medicina Interna
IRCCS Ospedale Maggiore di Milano
Via Pace, 9
Milan
20122
Italy

Study information

Study designInterventional pilot multicenter study
Primary study designInterventional
Secondary study designNon randomised study
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titleTo evaluate the efficacy, safety and tolerability of Hilterapia® (High Intensity Laser Therapy) in the chronic articular inflammatory processes in haemophilic adult patients: an interventional pilot multicentre study
Study objectivesPrevious experimental studies (Fortune, 2002) indicate how the laser can be antagonistic to degenerative phenomenon, experimentally induced, to stimulate neo-chondrogenisis with formation of simil-jalina cartilage and to induce synovial hyperplasia; these effects appear to be particularly related to variations in light intensity (power intensity: W/cm2) rather than when supplied in doses (Joule J/cm2).
Ethics approval(s)Ethics Comittee of the Foundation of the Institute of Medical Research of a Public Nature and the City Counil of Milan [Comitato di Etica della Fondazione IRCCS Ca´ Granda Ospedale Maggiore Policlinico di Milano], 22/03/2011
Health condition(s) or problem(s) studiedHaemophilia
InterventionTherapy with the equipment ASA-SH1 involves 9 applications (3 applications per week x 3 weeks) of Hilterapia® with the following operating parameters:
1. Fluence: 360 to 760 mJ/cm2
2. Frequency: 10 - 35 Hz
3. Total energy: 500 to 1,500 J
4. Time of application: 6 - 11 minutes
Subjects will be requested to attend 10 clinical visits in total: T1 (screening/first treatment), T2-T9 (HILT application visits) and T10 (final visit).
Intervention typeOther
Primary outcome measure1. Pain will be measured using the Visual Analogue Scale (VAS) score (0 = no pain, 10 = unbearable pain) at baseline (T1), T4, T7 and T10 visits
2. Nieschl’s Score and the articular state will be measured using Hemophilia Joint Health Score 2.0
Secondary outcome measuresNo secondary outcome measures
Overall study start date15/05/2011
Completion date31/12/2011

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants15 (11 participants had been recruited by the end of the study)
Key inclusion criteria1. Adult subjects with haemophilia A of any severity with or not suppressant
2. Age more than or equal to 18 years
3. Subjects who have been previously diagnosed with a chronic articular inflammatory process or hematoma
4. Subjects who have signed an informed written consent
Key exclusion criteriaSubjects with under way bleeding
Date of first enrolment15/05/2011
Date of final enrolment31/12/2011

Locations

Countries of recruitment

  • Italy

Study participating centre

IRCCS Ospedale Maggiore di Milano
Milan
20122
Italy

Sponsor information

Baxter (Italy)
Industry

Piazzale dell'Industria, 20
Rome
00144
Italy

Website http://www.baxter.com/
ROR logo "ROR" https://ror.org/02kf9ya90

Funders

Funder type

Industry

Baxter (Italy)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Editorial Notes

14/02/2017: Plain English summary added.
09/11/2012: The overall trial end date was changed from 31/12/2011 to 16/04/2012.